New Funding for Alzheimer’s Biomarker Research

Aimed at speeding up the research and development of improved testing and treatment for Alzheimer’s Disease, a coalition of philanthropists announced their commitment earlier this week to providing more than $30 million over the next three years to a newly created initiative, the Diagnostics Accelerator.

The goal for this initiative includes funding innovative, ground-breaking research into biomarkers for Alzheimer’s Disease, which can then be harnessed to drive early detection and diagnosis, and biomarker-specific drug development. Biomarkers may have the potential to provide more accurate, less expensive, and less invasive diagnostic testing options for Alzheimer’s Disease, in much the same way they are being used in the cancer field.

Funded by Bill Gates, the Alzheimer’s Drug Discovery Foundation co-founder Leonard Lauder, the Dolby family, the Charles and Helen Schwab foundation, and a team of other philanthropists, the Diagnostics Accelerator initiative will have the flexibility to funnel financial resources to cutting-edge research projects that might otherwise struggle to get funding from traditional governmental, charitable, and venture capital sources.

Along with this announcement came a call to action for the research community: send your research proposals in now to apply for funding.

For more information, visit